Related Experiment Video
Updated: Oct 25, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
PCSK9 Inhibition could be Effective for Acute Myocardial Infarction
Baris Gencer1,2, François Mach1
1Cardiology Division, Geneva University Hospitals, Geneva, Switzerland.
Abstract:
In this review, we explore the role of PCSK9 and the inhibition of PCSK9 in patients after acute myocardial infarction (MI). Despite the implementation of evidencebased therapies to improve outcomes, one-year mortality remains at 12-15%, and there is still a need to further reduce complications related to MI. Mechanistic and epidemiologic studies have suggested that the naturally occurring PCSK9 protein increases coronary plaque vulnerability through several pathways, including pro-inflammatory LDL-C oxidation and direct modification of plaque composition. PCSK9 inhibitors are a class of drugs with proven efficacy in patients with recent MI. The latest guidelines recommend the use of PCSK9 inhibitors in patients with recent MI early in the process of care to reduce LDL-C values and associated morbidity. The use of PCSK9 inhibition could be beneficial for mortality reduction after an acute MI and should be tested in an appropriately powered randomized controlled trial.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease V: Interprofessional Care
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome III: Diagnostic Studies
Myocarditis III: Medical Management

